Patent: 11,529,398

Summary for Patent: 11,529,398

Patent Claims:

see list of patent claims

Scope and claims summary:

Exploring United States Patent 11529398: Breakthroughs in Personalized Medicine and In-Silico Predictive Modeling Recently granted United States Patent 11529398, owned by AstraZeneca, promises significant advancements in the realm of personalized medicine. At the heart of this innovative patent lies an AI-powered algorithm that accurately predicts the efficacy of cancer therapies based on individual patient profiles. But let's dive deeper into the scope and claims of this groundbreaking patent. Scope: A Challenging Terrain The patented technology — dubbed Adaptive Dose Finder (ADF) — targets the intricate relationship between a patient's genetic makeup and their response to cancer treatments. By integrating gene expression data, clinical trial information, and AI-driven algorithms, ADF aims to revolutionize cancer treatment with precision and flexibility. Key Patent Claims: AI-Powered Predictive Modeling Four central claims exemplify the revolutionary potential of this patent: Claims of In-Silico Modeling: The ADF algorithm, developed using machine learning algorithms, is capable of predicting patient responses to cancer therapies by leveraging genomic and epigenomic data. Claims of Adaptive Therapy: The technology enables clinicians to adjust dosing regimens dynamically to optimize treatment efficacy for individual patients. Claims of Real-World Applications: The patented technology is proposed for use in clinical settings to support data-driven decision-making for cancer treatment. Claims of Expanded Patient Populations: ADF can predict treatment efficacies across various cancer types and patient demographics. Implications for Patient Care By harnessing the power of predictive modeling, United States Patent 11529398 (AstraZeneca) seeks to redefine personalized cancer treatment. The broader implications are multifaceted: Enhanced Treatment Effectiveness: By aligning treatment protocols with patient-specific genetic profiles, ADF enhances the likelihood of clinical success. Targeted Therapy Approaches: ADF streamlines the treatment landscape, reducing trial-and-error attempts and promoting the use of targeted therapies. Optimized Patient Outcomes: Proactive dosing adjustments through ADF can minimize drug toxicities and maximize quality of life for patients. Future Directions and Research Horizons The prospect of incorporating artificial intelligence (AI) into modern medicine sparks opportunities for groundbreaking translational research and expanding clinical applications. By pushing the boundaries of biopharmaceutical innovation, United States Patent 11529398 paves the way for a novel, high-resolution paradigm in personalized cancer therapy. A New Wave in Precision Oncology In an era dominated by rapid-paced genomic discoveries, the AI-driven framework underpinning United States Patent 11529398 redefines the future of oncotherapy. The groundbreaking technology illuminates uncharted paths toward more patient-centric care, foreshadowing transformative breakthroughs in disease management.

Details for Patent 11,529,398

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	July 30, 2010	11,529,398
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	November 20, 2015	11,529,398